ReviewFrontiers in pharmacology2026

From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.

Christiano Argano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.